Trump's 100% Drug Tariffs: The FDA Problem No One Is Talking About 

PDF

Why Mid-Sized Pharma and Biotech Need to Move Now

The headline was simple: On April 2, 2026, President Trump announced 100% tariffs on imported branded drugs and key drug ingredients. Most of the immediate reaction has focused on trade, geopolitics, and pricing. But for drug manufacturers—especially mid-sized branded pharma and specialty biotech—the more urgent risk is not at U.S. Customs. It is at FDA.

The tariff may be a trade policy. Your response to it is likely an FDA-regulated event.

The Tariff in 30 Seconds

While the details will evolve through implementing regulations and guidance, the framework as announced is straightforward:

• 100% tariffs on patented drugs and certain active ingredients
  Imported, patented branded drugs and many of their critical components now face a 100% duty.
• An “exemption ladder” tied to pricing and U.S. manufacturing
  Companies can avoid or reduce the tariff by:

• MFN pricing + U.S. manufacturing = 0% tariff
  If you agree to a “most-favored nation” pricing arrangement (or similar cost controls) and manufacture in the United States, you can qualify for full relief.
• Construction phase relief = 20% now, 100% in four years
  If you commit to building U.S. manufacturing capacity, tariffs may be reduced (e.g., 20%) during construction, ramping to 100% if you are not fully onshore within four years.

• Orphan drugs are largely exempt
  Many orphan-designated products fall outside the most burdensome tariff categories, reducing exposure for certain niche portfolios.
• Big Pharma has mostly already cut deals
  Large multinationals have leverage, relationships, and pre-existing strategies for onshoring or price concessions. Many have already engaged with the administration or anticipated this policy direction in earlier negotiations.

Who is most exposed?
Mid-sized branded pharmaceutical companies and specialty biotech. These companies lack the political and pricing leverage of Big Pharma, often rely heavily on ex-U.S. manufacturing (including for fill-finish or packaging), may depend on single-source overseas suppliers for APIs or biologic drug substances, and are less likely to have “shovel-ready” U.S. manufacturing plans and internal FDA regulatory depth.

The FDA Problem Nobody Is Talking About

The instinctive response to a 100% tariff is operational and commercial: “Let’s move manufacturing.” From a regulatory standpoint, however, almost every action you might take to mitigate tariff exposure is a postapproval change under FDA rules.

1. Moving Manufacturing is a Regulated Change

Any meaningful shift in your supply chain—especially for approved drugs and biologics—is more than a procurement decision.

• Changing manufacturing sites
  Moving drug substance, drug product, or even just fill-finish or packaging to a new facility is a chemistry, manufacturing, and controls (CMC)
• Postapproval change classification
  Many site changes are “major” postapproval changes under FDA’s guidance (e.g., for NDAs, ANDAs, and BLAs). That means:

• You must submit a Prior Approval Supplement (PAS) or equivalent
• You cannot ship commercial product from the new site until FDA has reviewed and approved that supplement

• Timing
  Major CMC changes often require:

• New validation batches
• Updated stability commitments
• Site documentation and, in many cases, pre-approval or surveillance inspections

Typical timelines range from 6–12+ months, and that assumes a complete and high-quality submission, no major questions or deficiencies from FDA, and no inspection findings that require remediation

The announced 2029 “onshoring” horizon may sound distant. In regulatory time, especially for biologics and complex products, it is uncomfortably close.

2. Changing API Suppliers is Not Plug-and-Play

If your response to the tariff is to switch to a U.S.-based API supplier or intermediate manufacturer, you face another FDA-regulated change.

• Your currently approved application identifies the API manufacturer and associated controls.
• A new supplier often requires:
• Comparative characterization of the API
• Process and impurity profile assessment
• Potential changes to specifications
• Validation of the revised manufacturing process for drug product

For small molecules, this may be manageable but still likely to trigger a PAS. For complex molecules, highly potent APIs, or controlled substances, the regulatory burden can grow significantly.

3. Biologics Are Even Harder

For biologics, the bar is higher:

• Process is product: Changes to manufacturing site, equipment, raw materials, or process parameters can alter the critical quality attributes of the biologic.
• Comparability studies: FDA expects robust analytical comparability and, in some cases, nonclinical or even clinical bridging data to demonstrate that product from the new site is “highly similar” to the original, without clinically meaningful differences.
• Risk of delays: If FDA is not satisfied with comparability, you may face additional data requests, extended review cycles, or limitations on the scope or timing of the site switch.

In other words, for biologics, “just move it to the U.S.” is rarely simple and never quick.

What Mid-Sized Pharma and Biotech Should Do Now

The 100% tariff is in effect. Your regulatory clock has already started, whether you have formally acknowledged it or not. A wait-and-see posture will, in many cases, convert a manageable business problem into a future crisis.

1. Map Your Supply Chain by Patent and Tariff Exposure

You need a concrete, product-by-product view—not assumptions.

• Identify products that:
• Are patented or rely on patented components
• Are manufactured, filled, finished, or packaged outside the U.S.
• Depend on ex-U.S. API, key starting materials, or critical intermediates
• Overlay tariff treatment:
• Which products/ingredients are subject to 100% tariffs?
• Which might qualify for partial or full relief?
• Which fall under orphan or other exemptions?

This mapping should be done in coordination with regulatory affairs (to understand current CMC commitments), supply chain and technical operations, trade counsel (to correctly interpret the tariff coverage), and finance and commercial (to assess margin impact and pricing constraints).

2. Start Your 120/180-Day Clock

For many companies, there are two hidden timers already running:

• Contractual and operational lead times (120–180 days)
  If you decide to call a CDMO, negotiate a U.S.-based supply agreement, or begin facility buildouts, you are already looking at months for due diligence, quality audits, and contract negotiation, and additional months to onboard, tech transfer, and validate processes.
• Regulatory lead times (6–12+ months)
  Once you know your preferred path, you still need data and documentation to support a PAS or other supplement, manufacturing and stability work at the new site, and FDA review and approval.

The effective planning window is therefore not four years; it is four years minus 12–24 months of operational and regulatory work. Companies that start now can sequence these steps rationally. Companies that wait until tariff costs become intolerable will be forced into compressed timelines with fewer options.

One of the most common—and costly—mistakes is treating the tariff as purely a trade and tax problem and looping in FDA regulatory and CMC expertise only after business decisions are made.

Instead:

• Integrate trade, regulatory, and operational planning from the outset.
• Before committing to a U.S. CDMO or site, ask:
• What type of FDA supplement will this change require?
• What data are needed to support it (validation, comparability, stability)?
• Can the site support inspection readiness on the required timeline?
• Are there packaging/labeling or serialization implications?
• Analyze multiple regulatory scenarios:
• Partial onshoring (e.g., fill-finish in the U.S., API still abroad)
• Staged transitions (e.g., second source first, full switch later)
• Hybrid models that balance tariff exposure and regulatory risk

Early FDA-focused planning can avoid committing to technically attractive but regulatorily impractical solutions, align your construction/tech transfer schedule with realistic FDA review timelines, and minimize disruption to commercial supply while the transition occurs

The Bottom Line

The new 100% tariffs are a trade problem. But the way you solve that trade problem—by moving manufacturing, changing suppliers, or restructuring your supply chain—is fundamentally an FDA problem.

For mid-sized pharma and specialty biotech, the risk is acute:

• You have fewer levers to negotiate special tariff or pricing deals.
• You are more likely to be reliant on single, ex-U.S. suppliers.
• You have less in-house bandwidth to navigate complex CMC and postapproval strategies under pressure.

This is not a problem for trade counsel to “solve” in isolation. The right team includes:

• Trade and customs counsel
• FDA regulatory and CMC counsel
• Internal technical operations, quality, and regulatory affairs
• Business, commercial, and finance stakeholders

They need to be in the same room now, not when tariff invoices are already hitting your P&L.

If you would like to assess your exposure, map your regulatory risk, or structure an onshoring pathway that aligns with FDA requirements and realistic timelines, our team at Maynard Nexsen can help you coordinate trade and FDA strategy from the outset—before the clock runs out.